MAURICIO SIMOES ABRAO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
32 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 32
- Endometriosis Classification, Staging and Reporting Systems: A Review on the Road to a Universally Accepted Endometriosis Classification † ‡(2021) VERMEULEN, N.; ABRAO, M. S.; EINARSSON, J. I.; HORNE, A. W.; JOHNSON, N. P.; LEE, T. T. M.; MISSMER, S.; PETROZZA, J.; TOMASSETTI, C.; ZONDERVAN, K. T.; GRIMBIZIS, G.; WILDE, R. L. De; WES, ESGE International working group of AAGL ESHRE andObjective: In the field of endometriosis, several classification, staging and reporting systems have been developed. Which endometriosis classification, staging and reporting systems have been published and validated for use in clinical practice? Data sources: A systematic PUBMED literature search was performed. Data were extracted and summarized. Methods of study selection: na Tabulation, integration and results: Twenty-two endometriosis classification, staging and reporting systems have been published between 1973 and 2021, each developed for specific, and different, purposes. There still is no international agreement on how to describe the disease. Studies evaluating the different systems are summarized showing a discrepancy between the intended and the evaluated purpose, and a general lack of validation data confirming a correlation with pain symptoms or quality of life for any of the current systems. A few studies confirm the value of the ENZIAN system for surgical description of deep endometriosis. With regards to infertility, the endometriosis fertility index has been confirmed valid for its intended purpose. Conclusion: Of the 22 endometriosis classification, staging and reporting systems identified in this historical overview, only a few have been evaluated for the purpose for which they were developed. The literature search was limited to PUBMED. Unpublished classification, staging or reporting systems, or those published in books were not considered. It can be concluded that there is no international agreement on how to describe endometriosis or how to classify it, and that most classification/staging systems show no or very little correlation with patient outcomes. This overview of existing systems is a first step in working towards a universally accepted endometriosis classification. © 2021
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist(2017) TAYLOR, H. S.; GIUDICE, L. C.; LESSEY, B. A.; ABRAO, M. S.; KOTARSKI, J.; ARCHER, D. F.; DIAMOND, M. P.; SURREY, E.; JOHNSON, N. P.; WATTS, N. B.; GALLAGHER, J. C.; SIMON, J. A.; CARR, B.; DMOWSKI, W. P.; LEYLAND, N.; ROWAN, J. P.; DUAN, W. R.; NG, J.; SCHWEFEL, B.; THOMAS, J. W.; JAIN, R. I.; CHWALISZ, K.BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies. METHODS We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the effects of two doses of elagolix - 150 mg once daily (lower-dose group) and 200 mg twice daily (higher-dose group) - as compared with placebo in women with surgically diagnosed endometriosis and moderate or severe endometriosis-associated pain. The two primary efficacy end points were the proportion of women who had a clinical response with respect to dysmenorrhea and the proportion who had a clinical response with respect to nonmenstrual pelvic pain at 3 months. Each of these end points was measured as a clinically meaningful reduction in the pain score and a decreased or stable use of rescue analgesic agents, as recorded in a daily electronic diary. RESULTS A total of 872 women underwent randomization in Elaris EM-I and 817 in Elaris EM-II; of these women, 653 (74.9%) and 632 (77.4%), respectively, completed the intervention. At 3 months, a significantly greater proportion of women who received each elagolix dose met the clinical response criteria for the two primary end points than did those who received placebo. In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P< 0.001 for all comparisons). In Elaris EM-I, the percentage of women who had a clinical response with respect to nonmenstrual pelvic pain was 50.4% in the lower-dose elagolix group and 54.5% in the higher-dose elagolix group, as compared with 36.5% in the placebo group (P < 0.001 for all comparisons); in Elaris EM-II, the corresponding percentages were 49.8% and 57.8%, as compared with 36.5% (P = 0.003 and P < 0.001, respectively). The responses with respect to dysmenorrhea and nonmenstrual pelvic pain were sustained at 6 months. Women who received elagolix had higher rates of hot flushes (mostly mild or moderate), higher levels of serum lipids, and greater decreases from baseline in bone mineral density than did those who received placebo; there were no adverse endometrial findings. CONCLUSIONS Both higher and lower doses of elagolix were effective in improving dysmenorrhea and nonmenstrual pelvic pain during a 6-month period in women with endometriosis-associated pain. The two doses of elagolix were associated with hypoestrogenic adverse effects. (Funded by AbbVie; Elaris EM-I and EM-II ClinicalTrials.gov numbers, NCT01620528 and NCT01931670.)
conferenceObject LONG-TERM SAFETYAND EFFICACY OF ELAGOLIX TREATMENT IN WOMEN WITH ENDOMETRIOSIS ASSOCIATED PAIN: PRIMARY RESULTS FROM TWO PHASE 3 EXTENSION STUDIES.(2017) SURREY, E.; TAYLOR, H. S.; GIUDICE, L. C.; SINGH, S.; ABRAO, M. S.; LESSEY, B. A.; DUAN, W. R.; PELOSO, P. M.; SCHWEFEL, B.; CHWALISZ, K.- LEUKOCYTE TELOMERE LENGTH IS LONGER IN PATIENTS WITH ENDOMETRIOSIS COMPARED TO CONTROLS.(2013) DRACXLER, R. C.; KALMBACH, K. H.; WANG, F.; ABRAO, M. S.; KEEFE, D. L.
conferenceObject The role of preoperative imaging in guiding laparoscopic excision of deep endometriosis(2017) ABRAO, M. S.; MYUNG, L.; FERNANDES, L. C.; GONCALVES, M.; ACCARDO, L.; BASSI, M.- An International Terminology for Endometriosis, 2021(2021) TOMASSETTI, C.; JOHNSON, N. P.; PETROZZA, J.; ABRAO, M. S.; I, J. Einarsson; HORNE, A. W.; LEE, T. T. M.; MISSMER, S.; VERMEULEN, N.; ZONDERVAN, K. T.; GRIMBIZIS, G.; WILDE, R. L. DeBackground: Different classification systems have been developed for endometriosis, using different definitions for the disease, the different subtypes, symptoms and treatments. In addition, an International Glossary on Infertility and Fertility Care was published in 2017 by the International Committee for Monitoring Assisted Reproductive Technologies (ICMART) in collaboration with other organisations. An international working group convened over the development of a classification or descriptive system for endometriosis. As a basis for such system, a terminology for endometriosis was considered a condition sine qua non. Objectives: The aim of the current paper is to develop a set of terms and definitions on endometriosis that would be the basis for standardisation in disease description, classification and research. Materials and Methods: The working group listed a number of terms relevant to be included in the terminology, documented currently used and published definitions, and discussed and adapted them until consensus was reached within the working group. Following stakeholder review, further terms were added, and definitions further clarified. Although definitions were collected through published literature, the final set of terms and definitions is to be considered consensus-based. After finalisation of the first draft, the members of the international societies and other stakeholders were consulted for feedback and comments, which led to further adaptations. Results: A list of 49 terms and definitions in the field of endometriosis is presented, including a definition for endometriosis and its subtypes, different locations, interventions, symptoms and outcomes. Endometriosis is defined as a disease characterised by the presence of endometrium-like epithelium and/or stroma outside the endometrium and myometrium, usually with an associated inflammatory process. Conclusions: The current paper outlines a list of 49 terms and definitions in the field of endometriosis. The application of the defined terms aims to facilitate harmonisation in endometriosis research and clinical practice. Future research may require further refinement of the presented definitions. What is new? A consensus based international terminology for endometriosis for clinical and research use.
- Reply: Should we also work on an international informed consent for endometriosis surgery?(2017) VANHIE, A.; MEULEMAN, C.; TOMASSETTI, C.; TIMMERMAN, D.; D'HOORE, A.; WOLTHUIS, A.; CLEYNENBREUGEL, B. Van; DANCET, E.; BROECK, U. Van den; TSALTAS, J.; RENNER, S. P.; EBERT, A. D.; CARMONA, F.; ABBOTT, J.; STEPNIEWSKA, A.; TAYLOR, H.; SARIDOGAN, E.; MUELLER, M.; KECKSTEIN, J.; PLUCHINO, N.; ZUPI, E.; DUNSELMAN, G.; ABRAO, M. S.; CHAPRON, C.; D'HOOGHE, T.
- Strengths and limitations of diagnostic tools for endometriosis and relevance in diagnostic test accuracy research(2022) PASCOAL, E.; WESSELS, J. M.; AAS-ENG, M. K.; ABRAO, M. S.; CONDOUS, G.; JURKOVIC, D.; ESPADA, M.; EXACOUSTOS, C.; FERRERO, S.; GUERRIERO, S.; HUDELIST, G.; MALZONI, M.; REID, S.; TANG, S.; TOMASSETTI, C.; SINGH, S. S.; BOSCH, T. van den; LEONARDI, M.Endometriosis is a chronic systemic disease that can cause pain, infertility and reduced quality of life. Diagnosing endometriosis remains challenging, which yields diagnostic delays for patients. Research on diagnostic test accuracy in endometriosis can be difficult due to verification bias, as not all patients with endometriosis undergo definitive diagnostic testing. The purpose of this State-of-the-Art Review is to provide a comprehensive update on the strengths and limitations of the diagnostic modalities used in endometriosis and discuss the relevance of diagnostic test accuracy research pertaining to each. We performed a comprehensive literature review of the following methods: clinical assessment including history and physical examination, biomarkers, diagnostic imaging, surgical diagnosis and histopathology. Our review suggests that, although non-invasive diagnostic methods, such as clinical assessment, ultrasound and magnetic resonance imaging, do not yet qualify formally as replacement tests for surgery in diagnosing all subtypes of endometriosis, they are likely to be appropriate for advanced stages of endometriosis. We also demonstrate in our review that all methods have strengths and limitations, leading to our conclusion that there should not be a single gold-standard diagnostic method for endometriosis, but rather, multiple accepted diagnostic methods appropriate for different circumstances. (c) 2022 International Society of Ultrasound in Obstetrics and Gynecology.
conferenceObject SPIRIT long-term extension study: two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain(2022) BECKER, C.; AS-SANIE, S.; ABRAO, M. S.; BROWN, E.; FERREIRA, J. C. Arjona; WAGMAN, R. B.; WANG, F.; PERRY, J. S.; JOHNSON, N.; GIUDUCE, L. C.- AAGL 2021 Endometriosis Classification: An Anatomy-based Surgical Complexity Score(2021) ABRAO, M. S.; ANDRES, M. P.; MILLER, C. E.; GINGOLD, J. A.; RIUS, M.; NETO, J. S.; CARMONA, F.Study Objective: To develop a new endometriosis classification system for scoring intraoperative surgical complexity and to examine its correlation with patient-reported pain and infertility. Design: Multicenter study of patients treated at 3 recognized endometriosis centers. Setting: Three specialized endometriosis surgical centers in São Paulo, Brazil and Barcelona, Spain. Patients: Patients aged 15 to 45 years with histologically proven endometriosis and no history of pelvic malignancy underwent laparoscopic treatment of endometriosis. Interventions: Demographic data and clinical history, including dysmenorrhea, noncyclic pelvic pain, dyspareunia, dysuria and dyschezia, were prospectively recorded. All patients were staged surgically according to the new 2021 American Association of Gynecologic Laparoscopists (AAGL) and revised American Society of Reproductive Medicine (ASRM) classification systems. The staging for each system was compared against a 4-level surgical complexity scale defined by the most complex procedure performed. Measurements and Main Results: A total of 1224 patients undergoing surgery met inclusion criteria. The AAGL score discriminated between 4 stages of surgical complexity with high reproducibility (κ = 0.621), whereas the ASRM score discriminated between the complexity stages with poor reproducibility (κ = 0.317). The AAGL staging system correlated with dysmenorrhea, dyspareunia, dyschezia, total pain score, and infertility comparably with the ASRM staging system. Conclusion: The AAGL 2021 Endometriosis Classification allows for identifying objective intraoperative findings that reliably discriminate surgical complexity levels better than the ASRM staging system. The AAGL severity stage correlates comparably with pain and infertility symptoms with the ASRM stage. © 2021 AAGL